Glucose Transporter Type 1 Deficiency Syndrome: SLC2A1 Gene Deletion/Duplication

Condition Description

Glucose transporter type 1 deficiency syndrome (Glut-1-DS) is characterized by infantile seizures that are resistant to treatment by anticonvulsants.  This is followed by delays in mental and motor development, head growth retardation, ataxia, dysarthria, spasticity, and uncontrolled eye movement before meals. The most important laboratory observation in Glut-1-DS is a reduced cerebrospinal fluid glucose concentration.  Affected infants appear normal at birth.  Seizures typically begin between one and four months of age.  The frequency, type, and severity of seizures vary among individuals with Glut-1-DS.  Additionally, cognitive impairment can range from learning difficulties to severe intellectual disability.

Mutation of the SLC2A1 (1p35-p31.3) gene cause Glut-1-DS.  Glut-1-DS is inherited in an autosomal dominant manner with the majority of mutations occurring de novo.  Affected parents have been reported with a mild or subclinical degree of impairment.

For patients with suspected Glut-1-DS, sequence analysis is recommended as the first step in mutation identification. For patients in whom mutations are not identified by full gene sequencing, deletion/duplication analysis is appropriate.

References:

Genes (1)

Your search may have returned a result for a gene alias. Click here for a full list of genes and their aliases.

Indications

This test is indicated for:
  • Confirmation of a clinical diagnosis of Glucose Transporter Type 1 Deficiency syndrome in an individual in whom sequence analysis was negative.
  • Carrier testing in adults with a family history of Glucose Transporter Type 1 Deficiency syndrome in whom sequence analysis was negative.

Methodology

DNA isolated from peripheral blood is hybridized to a CGH array to detect deletions and duplications. The targeted CGH array has overlapping probes which cover the entire genomic region.

Detection

Detection is limited to duplications and deletions. The CGH array will not detect point or intronic mutations. Results of molecular analysis must be interpreted in the context of the patient's clinical and/or biochemical phenotype.

Specimen Requirements

Listed below are EGL's preferred sample criteria. For any questions, please call 470.378.2200 and ask to speak with a laboratory genetic counselor (eglgc@egl-eurofins.com).
Submit only 1 of the following specimen types
DNA, Isolated
DNA

Requirements
Microtainer
3µg
Isolation using the Perkin Elmer™Chemagen™ Chemagen™ Automated Extraction method or Qiagen™ Puregene kit for DNA extraction is recommended.
Collection and Shipping
Refrigerate until time of shipment in 100 ng/µL in TE buffer. Ship sample at room temperature with overnight delivery.
Whole Blood (EDTA)
WBP

Requirements
EDTA (Purple Top)
Infants and Young Children (<2 years of age): 2-3 ml
Children > 2 years of age to 10 years old: 3-5 ml
Older Children & Adults: 5-10 ml
Autopsy: 2-3 ml unclotted cord or cardiac blood
Collection and Shipping
Ship sample at room temperature for receipt at EGL within 72 hours of collection. Do not freeze.

Special Instructions

Sequence analysis is required before deletion/duplication analysis by targeted CGH array. If sequencing is performed outside of EGL Genetics, please submit a copy of the sequencing report with the test requisition.
  • Sequence analysis of the SLC2A1 gene is available and is required before deletion/duplication analysis.  
  • Custom diagnostic mutation analysis (KM) is available to family members if mutations are identified by targeted mutation testing or sequencing analysis.
  • Prenatal testing is available only for known familial mutations to individuals who are confirmed carriers of mutations. Please contact the laboratory genetic counselor to discuss appropriate testing prior to collecting a prenatal specimen.

How to Order